A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Non-infectious Anterior Uveitis Clinical Trial

Official title:
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Status Completed

Clinical Trial Summary

This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%. Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02406209
Study type	Interventional
Source	Aldeyra Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 2015
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05042609` - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma	Phase 3
Completed	`NCT02309385` - Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis	Phase 1/Phase 2
Not yet recruiting	`NCT04426734` - Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids	Phase 4
Completed	`NCT04222712` - A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis	Phase 1/Phase 2
Completed	`NCT03131154` - SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.	Phase 3